drugset / Trial / NCT05407441
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Phase 1/2
Active not recruiting
49 enrolled
Susan Chi, MD
Bristol-Myers Squibb · collabEpizyme, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4. The names of the study drugs involved in this study are: * Tazemetostat (TAZVERIK) * Nivolumab (OPDIVO) * Ipilimumab (YERVOY)
Timeline
- Start
- 2023-08-10
- Primary completion
- 2027-02-01
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Tazemetostat | Small molecule | — | Oral |